Clinical trials: Follicular Lymphoma
Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world…
- Conditions
- Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
- Trial name
- ARIADNE (NCT05326308)
- Testing
- Zanubrutinib, Obinutuzumab
- Where
- 2 sites in Austria, Germany
- Volunteers
- 845 people
- Sponsor
- iOMEDICO AG
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT03010982
- Testing
- Tazemetostat and [14C] Tazemetostat
- Where
- 2 sites in United Kingdom
- Volunteers
- 3 people
- Sponsor
- Epizyme, Inc.
Follicular Lymphoma
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
- Trial name
- ELARA (NCT03568461)
- Testing
- tisagenlecleucel
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- ZUMA-1 (NCT02348216)
- Testing
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 307 people
- Sponsor
- Kite, A Gilead Company
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Primary Cutaneous Follicle Centre Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT03999697
- Testing
- Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Non-Hodgkin Lymphoma
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and…
- Trial name
- BIANCA (NCT03610724)
- Testing
- Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
- Where
- 26 sites in United States, Australia and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Large-Cell, Diffuse
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the safety and efficacy of ofatumumab used in combination with ifosfamide, carboplatin, etoposide (ICE) or dexamethasone, cytarabine, cisplatin (DHAP) salvage chemotherapy regimens in…
- Trial name
- NCT00823719
- Testing
- ofatumumab + ICE, ofatumumab + DHAP
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Myopia, Myopia, Moderate
Software Refraction With Mobilerone Versus Retinoscopy
Software refraction in the mobilerone for myopia and astigmatism is a novel medical device for myopia adults and elder children with or without astigmatism.
- Conditions
- Myopia, Myopia, Moderate, Astigmatism
- Trial name
- SRMR (NCT06059521)
- Testing
- Software refraction with Eye Test Technology in a mobilerone, Retinoscopy
- Where
- 3 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Beijing Airdoc Technology Co., Ltd.
Relapsed/Refractory Follicular Lymphoma With EZH2
Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma
Treating Relapsed/Refractory Follicular Lymphoma with Tazemetostat
- Trial name
- NCT05467943
- Testing
- Tazemetostat
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Hutchmed
Non-Hodgkin Lymphoma, Burkitt's Lymphoma
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2).
- Conditions
- Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02669017
- Testing
- ADCT-402
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 183 people
- Sponsor
- ADC Therapeutics S.A.
Follicular Lymphoma, Refractory Follicular Lymphoma
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
The purpose of this research study is to learn about the effectiveness and safety of the study drug, tazemetostat, in adults with relapsed/refractory follicular lymphoma whose tumours do not have an "EZH2 gain-of-function"…
- Trial name
- Mandolin (NCT06068881)
- Testing
- Tazverik (Tazemetostat)
- Sponsor
- Epizyme, Inc.
Colitis, Ulcerative
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
The purpose of this study is to determine whether COLAL-PRED is a safe and effective treatment for patients with moderate to severe ulcerative colitis.
- Trial name
- NCT00676832
- Testing
- COLAL-PRED
- Where
- 89 sites in United States
- Volunteers
- 190 people
- Sponsor
- Prometheus Laboratories
Lymphoma
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
- Trial name
- CITADEL-203 (NCT03126019)
- Testing
- Parsaclisib
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 126 people
- Sponsor
- Incyte Corporation
Follicular Lymphoma
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma
- Trial name
- NCT06368167
- Testing
- SHR2554
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Psoriasis
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.
- Trial name
- ADVANCE (NCT03721172)
- Testing
- Apremilast
- Where
- 64 sites in United States, Canada
- Volunteers
- 595 people
- Sponsor
- Amgen
Hemorrhoid
Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure
Trial Objectives The primary objectives of this clinical trial are to estimate the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set: overall performance defined by the successful creation of a normal staple line safety as…
- Trial name
- NCT01169311
- Testing
- Hemorrhoidopexy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Medtronic - MITG
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Asthma
SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults
This study will compare during 12 weeks, two treatment strategies for Initial Maintenance Therapy : fluticasone propionate alone or the salmeterol/fluticasone propionate combination in adults with moderate persistent asthma
- Trial name
- NCT00461500
- Testing
- Salmeterol xinafoate/fluticasone propionate combination, Fluticasone propionate
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Follicular
To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan
This study is a Phase 3 prospective, randomised, parallel-group, active controlled, double blind, multicentre, international study with 2 coprimary endpoints designed to demonstrate equivalence in pharmacokinetics (Part 1), as…
- Trial name
- rituximab (NCT02162771)
- Testing
- Rituxan, CT-P10, Cyclophosphamide
- Volunteers
- 140 people
- Sponsor
- Celltrion